The University of Chicago Header Logo

Connection

Mark J. Ratain to Clinical Trials, Phase I as Topic

Back to Details
This is a "connection" page, showing publications Mark J. Ratain has written about Clinical Trials, Phase I as Topic.
Mark J. Ratain
Connection Strength
4.335
Clinical Trials, Phase I as Topic
  1. Reply to T.A. Yap et al. J Clin Oncol. 2016 07 10; 34(20):2432-3.
    View in: PubMed
    Score: 0.524
  2. Casting doubt on the scientific utility of post-treatment biopsies in phase 1 trials. Clin Adv Hematol Oncol. 2016 Feb; 14(2):78-9.
    View in: PubMed
    Score: 0.515
  3. Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials. J Clin Oncol. 2016 Feb 01; 34(4):369-74.
    View in: PubMed
    Score: 0.510
  4. Harmonization of Renal Function Assessment Is Needed During Early Clinical Development of Oncology Drugs. J Clin Oncol. 2016 Jan 10; 34(2):103-4.
    View in: PubMed
    Score: 0.509
  5. Targeted therapies: redefining the primary objective of phase I oncology trials. Nat Rev Clin Oncol. 2014 Sep; 11(9):503-4.
    View in: PubMed
    Score: 0.465
  6. Biomarkers in phase I oncology trials: signal, noise, or expensive distraction? Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6545-8.
    View in: PubMed
    Score: 0.292
  7. Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials? J Clin Oncol. 2018 08 20; 36(24):2483-2491.
    View in: PubMed
    Score: 0.152
  8. New phase I trial methodology. Semin Oncol. 1997 Apr; 24(2):253-61.
    View in: PubMed
    Score: 0.140
  9. Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials. Clin Cancer Res. 2016 Feb 01; 22(3):527-9.
    View in: PubMed
    Score: 0.126
  10. Prognostic factors for survival in patients treated in phase I clinical trials. Cancer. 1994 Oct 01; 74(7):1965-73.
    View in: PubMed
    Score: 0.117
  11. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst. 1993 Oct 20; 85(20):1637-43.
    View in: PubMed
    Score: 0.110
  12. Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision. J Natl Cancer Inst. 1993 Feb 03; 85(3):217-23.
    View in: PubMed
    Score: 0.105
  13. Dose-escalation models for combination phase I trials in oncology. Eur J Cancer. 2010 Nov; 46(16):2870-8.
    View in: PubMed
    Score: 0.088
  14. Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making. J Clin Oncol. 2007 Feb 10; 25(5):548-54.
    View in: PubMed
    Score: 0.069
  15. Phase II oncology trials: let's be positive. Clin Cancer Res. 2005 Aug 15; 11(16):5661-2.
    View in: PubMed
    Score: 0.062
  16. Inside information: Financial conflicts of interest for research subjects in early phase clinical trials. J Natl Cancer Inst. 2004 May 05; 96(9):656-61.
    View in: PubMed
    Score: 0.057
  17. Estimation of the glomerular filtration rate in cancer patients: a new formula for new drugs. J Clin Oncol. 2003 Jul 15; 21(14):2633-5.
    View in: PubMed
    Score: 0.054
  18. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022. Ann Oncol. 2023 01; 34(1):48-60.
    View in: PubMed
    Score: 0.051
  19. Endostatin: are the 2 years up yet? J Clin Oncol. 2002 Sep 15; 20(18):3758-60.
    View in: PubMed
    Score: 0.051
  20. Rationale for phase I study of UFT plus leucovorin and oral JM-216. Oncology (Williston Park). 1997 Sep; 11(9 Suppl 10):26-9.
    View in: PubMed
    Score: 0.036
  21. Learning from our patients: one participant's impact on clinical trial research and informed consent. Ann Intern Med. 1997 Jun 01; 126(11):892-7.
    View in: PubMed
    Score: 0.035
  22. Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose. J Clin Oncol. 1996 Sep; 14(9):2622-3.
    View in: PubMed
    Score: 0.034
  23. Data modifications to phase I study of suramin. J Clin Oncol. 1996 Sep; 14(9):2623-4.
    View in: PubMed
    Score: 0.034
  24. Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol. 1995 May; 13(5):1062-72.
    View in: PubMed
    Score: 0.031
  25. Pushing the envelope: informed consent in phase I trials. Ann Oncol. 1995 Apr; 6(4):321-3.
    View in: PubMed
    Score: 0.030
  26. Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials. J Natl Cancer Inst. 1994 Nov 16; 86(22):1685-93.
    View in: PubMed
    Score: 0.030
  27. A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. Pharmacogenet Genomics. 2014 Feb; 24(2):129-32.
    View in: PubMed
    Score: 0.028
  28. Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs. Clin Cancer Res. 2013 Nov 01; 19(21):6039-43.
    View in: PubMed
    Score: 0.027
  29. Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons. J Clin Oncol. 1992 Nov; 10(11):1810-6.
    View in: PubMed
    Score: 0.026
  30. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst. 1999 Aug 04; 91(15):1281-7.
    View in: PubMed
    Score: 0.010
  31. Study of cohort-specific consent and patient control in phase I cancer trials. J Clin Oncol. 1998 Jul; 16(7):2305-12.
    View in: PubMed
    Score: 0.010
  32. Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion. Cancer Chemother Pharmacol. 1993; 31(4):283-8.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.